Immunological challenges for peptide-based immunotherapy in glioblastoma
Related Experiment Video
Updated: May 7, 2026
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Malte Mohme1, Marian C Neidert, Luca Regli
1Department of Neurosurgery, University Hospital Zurich, 8091 Zurich, Switzerland; Center for Molecular Neurobiology Hamburg, University Medical Center Eppendorf, 20251 Hamburg, Germany.
Abstract:
Glioblastoma is the most aggressive primary tumor of the central nervous system with a medium overall survival of 7-15 months after diagnosis. Since tumor cells penetrate the surrounding brain tissue, complete surgical resection is impossible and tumor recurrence is almost a certainty. New treatment modalities are therefore needed, and these should be able to trace, identify, and kill dispersed tumor cells with great accuracy. Immunological approaches in principle meet these needs. Unfortunately, due to profound tumor-associated mechanisms of immunosuppression and -evasion, immunotherapeutic strategies like peptide vaccination have so far not been translated into clinical success. If future, peptide-based vaccination approaches shall be successful in glioblastoma therapy, multiple questions need to be solved including identification of suitable antigens, route and mode of vaccination, preparation of the tumor-bearing "host" and antagonizing, as much as this is possible, glioblastoma-associated mechanisms of immune evasion and poor vaccination response. In this review we will address the immunological challenges of glioblastoma and discuss key aspects that have rendered successful immunotherapy difficult in the past.
Insights
Glioblastoma immunotherapy faces challenges due to tumor immune evasion. Overcoming these hurdles is key for developing effective peptide vaccination strategies against this aggressive brain cancer.
Area of Science:
- Neuro-oncology
- Immunology
- Cancer Therapy
Background:
- Glioblastoma is an aggressive brain tumor with poor prognosis, necessitating novel treatments.
- Complete surgical removal is impossible due to infiltrating tumor cells, leading to inevitable recurrence.
- Current treatments have limited efficacy, highlighting the need for advanced therapeutic modalities.
Purpose of the Study:
- To review the immunological challenges hindering glioblastoma immunotherapy.
- To discuss critical factors for successful future peptide-based vaccination strategies in glioblastoma treatment.
Main Methods:
- Review of existing literature on glioblastoma immunology and immunotherapy.
- Analysis of tumor-associated immunosuppression and immune evasion mechanisms.
- Discussion of key aspects for improving peptide vaccination efficacy.
Main Results:
- Glioblastoma exhibits significant tumor-associated immunosuppression and immune evasion.
- Previous peptide vaccination attempts have not achieved clinical success.
- Several critical questions regarding antigen selection, vaccination protocols, and immune response modulation remain.
Conclusions:
- Glioblastoma's immune microenvironment presents major obstacles to immunotherapy.
- Future success in glioblastoma peptide vaccination requires addressing antigen identification, delivery methods, host preparation, and immune evasion mechanisms.
